Jonitha Gardner
Amgen
15 Papers
78 Citations
Jonitha Gardner is an academic researcher from Amgen. The author has contributed to research in topics: FGF21 & Knockout mouse. The author has an hindex of 11, co-authored 15 publications.
Chat about Author
Papers
Characterization of a FGF19 Variant with Altered Receptor Specificity Revealed a Central Role for FGFR1c in the Regulation of Glucose Metabolism
Hongfei Ge,Helene Baribault,Steven Vonderfecht,Bryan Lemon,Jennifer Weiszmann,Jonitha Gardner,Ki Jeong Lee,Jamila Gupte,Paramita Mookherjee,Minghan Wang,Jackie Sheng,Xinle Wu,Yang Li +12 more
TL;DR: The results are the first direct demonstration of the central role of the βKlotho/FGFR1c receptor complex in glucose and lipid regulation, and strongly suggest that activation of this receptor complex alone might be sufficient to achieve all the metabolic functions of endocrine FGF molecules.
Fibroblast Growth Factor Receptor 4 (FGFR4) Deficiency Improves Insulin Resistance and Glucose Metabolism under Diet-induced Obesity Conditions
Hongfei Ge,Jun Zhang,Yan Gong,Jamila Gupte,Jay Ye,Jennifer Weiszmann,Kim Samayoa,Suzanne Coberly,Jonitha Gardner,Huilan Wang,Tim Corbin,Danny Chui,Helene Baribault,Yang Li +13 more
TL;DR: It is shown thatFGFR4 deficiency in mice leads to improvement in glucose metabolism, insulin sensitivity, and reduction in body weight under high fat conditions, and the results described herein suggest that FGFR4 antagonists alone, or in combination with other agents, could serve as a novel treatment for diabetes.
64
Dual actions of fibroblast growth factor 19 on lipid metabolism.
Xinle Wu,Hongfei Ge,Helene Baribault,Jamila Gupte,Jennifer Weiszmann,Bryan Lemon,Jonitha Gardner,Preston Fordstrom,Jie Tang,Mingyue Zhou,Minghan Wang,Yang Li +11 more
TL;DR: It is proposed that FGF19 has lipid-raising and lipid-lowering actions mediated through different FGF receptors and target tissues, and the results described here provide a potential mechanism that may explain the inconsistency in the reported effects of FGF 19 on lipid metabolism.
60
Patent
Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta-klotho
Yang Li,Xinle Wu,Hongfei Ge,Helene Baribault,Bryan Lemon,Jackie Sheng,Steven Vonderfecht,Jennifer Weiszmann,Jonitha Gardner,Ki Jeong Lee +9 more
- 20 Feb 2012
TL;DR: In this article, methods of identifying compounds that specifically modulate the interaction of FGFR1 and β-Klotho are disclosed, and the identified compounds can be useful in treating metabolic diseases and disorders that involve the interaction between FGFR 1 and β Klotho, in various embodiments the metabolic disease or disorder is diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
25
A unique FGF23 with the ability to activate FGFR signaling through both αKlotho and βKlotho.
Xinle Wu,Jennifer Weiszmann,Hongfei Ge,Helene Baribault,Jennitte Stevens,Nessa Hawkins,Steven Vonderfecht,Jonitha Gardner,Jamila Gupte,Jackie Sheng,Minghan Wang,Yang Li +11 more
TL;DR: The results suggest that βKlotho/FGFR1c or FGFR2c receptor complexes are sufficient for glucose regulation and raises an interesting concept of designing an FGF molecule that may be able to address multiple diseases simultaneously.
22